Floatz logo

Benserazide

Decreased Processing Speed

New York State Psychiatric InstituteSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Decreased Processing Speed cohort.

Asset / SponsorPhaseRating
LEVODOPA
New York State Psychiatric Institute
Phase 4BB

Same molecule, other indications

Benserazide is also rated in:

Parkinson DiseaseDormant
BBB
Indicative ·
76 / 100
View asset →
Parkinson diseaseDormant
BB
Indicative ·
69 / 100
View asset →
DysthymiaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →